Maxim Group reaffirmed their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report issued on Thursday, October 19th.
GILD has been the topic of a number of other reports. Jefferies Group LLC reissued a hold rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 11th. Leerink Swann lifted their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the stock a market perform rating in a report on Thursday, October 19th. BMO Capital Markets reiterated an outperform rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. BidaskClub upgraded shares of Gilead Sciences from a strong sell rating to a sell rating in a report on Thursday, June 22nd. Finally, J P Morgan Chase & Co restated an overweight rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of Buy and an average target price of $85.68.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.04% during midday trading on Thursday, reaching $77.07. The company’s stock had a trading volume of 22,760,672 shares. The stock has a 50-day moving average price of $82.01 and a 200 day moving average price of $73.09. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a market capitalization of $100.65 billion, a PE ratio of 8.37 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 59.94%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the business posted $2.75 earnings per share. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences will post $8.79 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Earns Hold Rating from Maxim Group” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/10/28/maxim-group-reaffirms-hold-rating-for-gilead-sciences-inc-gild.html.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.70%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.69%.
In other news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock valued at $36,338,919 in the last three months. 1.30% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Beech Hill Advisors Inc. lifted its position in Gilead Sciences by 52.4% during the 3rd quarter. Beech Hill Advisors Inc. now owns 10,475 shares of the biopharmaceutical company’s stock valued at $849,000 after acquiring an additional 3,600 shares during the period. Bremer Trust National Association lifted its position in Gilead Sciences by 18.6% during the 3rd quarter. Bremer Trust National Association now owns 7,302 shares of the biopharmaceutical company’s stock valued at $592,000 after acquiring an additional 1,146 shares during the period. Van Cleef Asset Management Inc lifted its position in Gilead Sciences by 1.7% during the 3rd quarter. Van Cleef Asset Management Inc now owns 66,656 shares of the biopharmaceutical company’s stock valued at $5,400,000 after acquiring an additional 1,108 shares during the period. Fortaleza Asset Management Inc. purchased a new position in Gilead Sciences during the 3rd quarter valued at about $1,288,000. Finally, SOL Capital Management CO lifted its position in Gilead Sciences by 7.5% during the 3rd quarter. SOL Capital Management CO now owns 10,770 shares of the biopharmaceutical company’s stock valued at $873,000 after acquiring an additional 750 shares during the period. 73.88% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.